Exelixis | EXEL - Assets


Exelixis reported $2.82B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
AstraZeneca USD 114.46B 2.03B Sep/2025
Bayer EUR 104.21B 1.03B Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Eisai JPY 1.44T 28.38B Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Exelixis USD 2.82B 145.47M Sep/2025
Genmab DKK 6.46B 122M Jun/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
Incyte USD 6.33B 509M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.14B 125M Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
Ultragenyx Pharmaceutical USD 1.19B 115.82M Sep/2025
Xencor USD 868.81M 10.61M Sep/2025